Skip to main content

Table 2 Regorafenib 10 mg/kg/day reduces mean microvessel density, cell proliferation (p histone H3 Ser10-positive cells) and apoptosis (cleaved PARP-positive cells) in patient-derived gastric cancer xenograft models

From: Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer

  Mean (SE) microvessel densitya Mean (SE) p-histone H3 Ser10-positive cells, % Mean (SE) cleaved PARP-positive cells, %
Xenograft model Vehicle Reg 10 Fold difference Vehicle Reg 10 Fold difference Vehicle Reg 10 Fold difference
GC09-0109 20.0 (6.0) 2.0 (0.5)* 10.0 8.3 (1.6) 2.1 (0.7)* 4.0 1.2 (0.5) 2.1 (0.6) 1.8
GC28-1107 11.4 (1.8) 2.4 (0.8)* 4.8 4.6 (0.4) 1.4 (0.6)* 3.3 0.3 (0.1) 7.3 (1.5)* 24.3
GC22-0808 23.0 (7.0) 2.1 (0.7)* 11.0 8.9 (2.1) 8.2 (1.4) 1.1 2.7 (1.5) 6.8 (2.4)* 2.5
GC30-0309 16.0 (4.0) 5.0 (2.0)* 3.2 17.8 (8.0) 5.3 (2.0)* 3.4 1.4 (0.7) 17.2 (4.0)* 12.3
GC10-0608 24.0 (5.0) 2.7 (1.0)* 8.9 10.3 (3.0) 2.1 (0.4)* 4.9 0.9 (0.4) 4.8 (1.4)* 5.3
GC17-0409 28.0 (7.0) 5.0 (1.4)* 5.6 15.3 (5.0) 4.8 (1.1)* 3.2 0.4 (0.2) 31.0 (10.0)* 77.5
GC05-0208B 43.0 (11.0) 4.0 (1.2)* 10.8 4.8 (0.9) 3.1 (0.8) 1.5 3.1 (0.9) 9.9 (3.0)* 3.2
GC23-0909 16.1 (2.8) 5.2 (1.0)* 3.1 13.9 (2.8) 5.7 (1.7)* 2.4 0.3 (0.1) 7.3 (1.9)* 24.3
  1. PARP: poly-(ADP ribose) polymerase; Reg 10: regorafenib 10 mg/kg/day; SE: standard error
  2. *p < 0.05 versus vehicle
  3. aNumber of immunostained vessels in ten 0.159 mm2 fields from ten randomly selected tumors at a magnification of × 100